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Several chemokines are used for immunotherapy against cancers because they 
can attract immune cells such as dendritic and cytotoxic T cells to augment immune responses. 
Radio-frequency ablation (RFA) is used to locally eliminate cancers such as hepatocellular 
carcinoma (HCC), renal cell carcinoma, and lung cancer. Because HCC often recurs even after 
an eradicative treatment with RFA, additional immunotherapy is necessary. We treated 
tumor-bearing mice by administering ECI301, an active variant of CC chemokine ligand 3 
(CCL3), after RFA. Mice were injected subcutaneously with BNL, a murine hepatoma cell line, 
in the bilateral flank. After the tumor became palpable, RFA was performed on the tumor of one 
flank with or without ECI301. RFA alone eliminated the treated ipsilateral tumors and retarded 
the growth of contralateral non-RFA-treated tumors accompanied with massive T-cell 
infiltration. Injection of ECI301 augmented RFA-induced antitumor effect against 
non-RFA-treated tumors when administered to wild-type or CCR5-deficient but not 
CCR1-deficient mice. ECI301 also increased CCR1-expressing CD11c+ cells in peripheral 
blood and RFA-treated tumors after RFA. Deficiency of CCR1 impairs accumulation of 
CD11c+, CD4+, and CD8+ cells in RFA-treated tumors. Furthermore, in IFN-γ-enzyme-linked 
immunospot assay, ECI301 augmented tumor-specific responses after RFA whereas deficiency 
of CCR1 abolished this augmentation. Thus, we proved that ECI301 further augments 




Chemokines are a class of candidate molecules for immunotherapy. Chemokines are 
presumed to play an essential role in the regulation of leukocyte trafficking and dendritic cell: T 
cell interactions (1-4). In animal experiments, intratumoral use of chemokines, such as 
monocyte chemoattractant protein (MCP)-1/CCL2, macrophage inflammatory protein 
(MIP)-1/CCL3, or MIP-3/CCL20, succeed in decreasing tumorigenesis accompanied with 
increase in the numbers of tumor-infiltrating dendritic, natural killer, or T cells (5-7). Thus, 
application of chemokines in immunotherapy is promising but needs further refinement before 
they can be used in clinical situations. 
Radio-frequency ablation (RFA) is an eradicative treatment against cancers, such as 
hepatocellular carcinoma (HCC), renal cell carcinoma, and lung cancer. RFA of HCC can 
generate HCC-specific T cells in peripheral blood (8). Activation of dendritic cells in human 
peripheral blood is also observed after this treatment (9). Thus, RFA can induce immunogenic 
tumor cell death and subsequently tumor-specific immune responses (8-11). However, 
multicentric development of HCC in the cirrhotic liver frequently results in tumor recurrence 
even after the apparent curative treatment of HCC by RFA (12). These observations suggest that 
RFA-induced tumor-specific immune responses are often not sufficient to prevent tumor 
recurrence. Thus, additional treatment modalities are required to augment HCC-specific 
immune responses. 
CCL3/MIP-1 can augment immune responses but problems arise because of its 
tendency to form large aggregates at high concentrations when administered systemically. 
Unlike human naïve CCL3, BB-10010 is generated by a single amino acid substitution of Asp26 
to Ala and exhibits similar biological potencies, but rarely forms large aggregates (13). Based on 
its activity to mobilize bone marrow cells to peripheral blood, randomized clinical trials were 
performed to examine whether the combined administration of BB-10010 and chemotherapeutic 
agents can protect against chemotherapy-induced neutropenia. However, the myeloprotective 
effects of BB-10010 were not sufficient to warrant its use with chemotherapy (14). 
Concomitantly, several lines of evidence reveal that the administration of human recombinant 
CCL3 can mobilize activated T-cell and dendritic cell precursors into circulation (15, 16).  
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ECI301, which has the same amino acid sequence as BB-10010, was generated using 
the fission yeast (Schizosaccharomyces pombe) expression system. ECI301 can augment 
irradiation-induced tumor regression when administered systemically to mice bearing multiple 
subcutaneous tumors (17). Of interest is the fact that the effects were observed in both 
unirradiated as well as irradiated tumors. Thus, systemic ECI301 treatment can augment 
irradiation-induced tumor-specific systemic immunity. These observations prompted us to 
investigate the effects of ECI301 on RFA-treated mice. Here, we demonstrate that ECI301 




MATERIALS AND METHODS 
 
Mice 
Specific pathogen-free 7- to 9-week-old female BALB/c mice were purchased from Charles 
River Japan (Yokohama, Japan) and designated as wild-type (WT) mice. BALB/c-nu/nu mice 
were purchased from CLEA Japan. CCR1-deficient (CCR1-/-) mice were a gift from Dr. Philip 
M. Murphy [National Institute of Allergy and Infectious Disease, National Institute of Health 
(NIAID, NIH), Bethesda, MD, USA], CCR5-deficient (CCR5-/-) mice were a gift from Dr. 
Kouji Matsushima (Department of Molecular Preventive Medicine, Tokyo University, Tokyo, 
Japan). All mice were backcrossed to BALB/c mice for 8 to 10 generations. All animal 
experiments were performed under specific pathogen-free conditions in accordance with the 
Guidelines for the Care and Use of Laboratory Animals of Kanazawa University (Japan).  
 
Tumor cell line 
A murine HCC cell line, BNL 1ME A.7R.1 (BNL) was purchased from American Type Culture 
Collection in 1998 and kept at low passage throughout the study. The cells were screened for 
bacteria, fungus and mycoplasma contamination by direct culture method in 2006 before a start 
of the study. The cells were cultured in Dulbecco’s modified essential medium (Sigma Chemical 
Co., St. Louis, MO) containing 10% fetal bovine serum, 0.1 mM nonessential amino acids, 1 
μM sodium pyruvate, 2 mM L-glutamine, 50 μg/ml streptomycin and 100 U/ml penicillin 
(Gibco, Long Island, NY).  
 
Animal models 
ECI301 was generated as previously described and provided by Effector Cell Institute, Inc 
(Tokyo, Japan). (17, 18). Left and right flanks of 7- to 9-week-old female WT, CCR1-/-,  
CCR5-/- and nu/nu mice were injected subcutaneously with 5 × 105 BNL cells in 100 μl PBS. 
Fourteen days later, when tumor size reached a diameter of 6–8 mm, tumors of one flank were 
treated using a radio frequency (RF) generator (RITA 500PA; RITA Medical Systems, Fremont, 
CA) and needle as described below. On day 0, 2, 4 after RFA, 20 μg of ECI301 in 100 μl PBS 
was injected intravenously via the tail vein, while mice treated with RFA alone were injected 
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with 100μl of PBS. Untreated tumor-bearing mice were used as controls. In another schedule, 2 
μg of ECI301 in 100 μl PBS was injected intravenously from day 0 to 4 (5 consecutive days). 
Sizes of non-RFA-treated tumors on the contralateral flank were evaluated twice a week using 
calipers and tumor volumes were calculated using the following formula:  
Tumor volume (mm3) = (longest diameter) × (shortest diameter)2/2 
RFA-treated or non-RFA-treated tumors were excised at the indicated time intervals for 
immunohistochemical analysis and quantitative real-time RT-PCR. Spleens and peripheral blood 
were removed from the mice at the indicated time intervals for flow cytometric analysis and 
enzyme-linked immunospot assay (ELISPOT). 
 
RFA 
Mice were anesthetized by intraperitoneal injection of Somnopentyl® (Schering-Plough Animal 
Health, Boxmeer, Netherlands) and carefully shaved in the tumor area. After placing the mice 
onto an aluminum plate attached with an electricity-conducting pad, an RFA needle of 
expandable electrode with maximum dimension of 20 mm (70SB 2 cm; RITA Medical Systems) 
was inserted into the middle of the tumors, and expanded at 2 or 3 mm. RFA treatments were 
performed using an RF generator at a power output of 25 W for 1.5 min and the temperature of 
the needle tips reached 70−80°C. 
 
Immunohistochemical analysis 
The removed tumor tissues were embedded in Sakura Tissue-Tek OCT compound (Sakura 
Finetek, Torrance, CA) as frozen tissues. Cryostat sections of the frozen tissues were fixed with 
4% paraformaldehyde (PFA) in PBS and stained with rat anti-mouse CD4 (BD Biosciences, San 
Diego, CA, USA), rat anti-mouse CD8a (BD Biosciences), hamster anti-mouse CD11c (BD 
Biosciences), and rat anti-mouse F4/80 antibodies (Serotec, Oxford, UK) overnight at 4°C. The 
sections were then incubated with biotinylated rabbit anti-rat IgG (Dako Cytomation, Tokyo, 
Japan) or biotinylated mouse anti-hamster IgG (BD Biosciences) for 1 h at room temperature. 
The immune complexes were visualized using the Catalyzed Signal Amplification System 
(Dako Cytomation) or the Vectastain Elite ABC and DAB substrate kits (Vector Laboratories, 
Burlingame, CA, USA) according to the manufacturer’s instructions. As a negative control, rat 
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IgG (Cosmo Bio, Tokyo, Japan), or hamster IgG (BD Biosciences) was used instead of specific 
primary antibodies. The numbers of positive cells in each animal were counted in 10 randomly 
selected fields at 400-fold magnification by an examiner without any prior knowledge of the 
experimental procedures.  
 
Double-color immunofluorescence analysis 
Tumor tissues were embedded in the OCT compound as frozen tissues. After fixation with 4% 
PFA/PBS, cryostat sections were stained with the combinations of anti-CD4 and goat 
anti-mouse CCR1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-CD8a and anti-CCR1, 
anti-F4/80 and anti-CCR1, PE-conjugated hamster anti-CD11c (BD Biosciences) and 
anti-CCR1, anti-F4/80 and goat anti-mouse CCL3 (R&D Systems, Minneapolis, MN), and 
anti-F4/80 and goat anti-mouse CCL4 antibodies (R&D). After extensive washing, AF488 
donkey anti-rat IgG (Invitrogen, Carlsbad, CA) was used as a secondary antibody to detect 
CD4+, CD8a+, or F4/80+ cells. Simultaneously, AF546- or AF488-donkey anti-goat IgG 
(Invitrogen) was used to detect CCR1+, CCL3+, or CCL4+ cells. The sections were observed 
using a confocal microscope (LSM 510 META, Zeiss, NY).  
 
Quantitative real-time RT-PCR 
Total RNA was extracted from the resected tumor using RNeasy Mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. After treating the RNA preparations 
with ribonuclease-free deoxyribonuclease (DNase) I (Qiagen) to remove residual DNA, cDNA 
was synthesized as described previously (19). Quantitative real-time PCR was performed on a 
StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA) using the 
comparative CT quantification method. TaqMan® Gene Expression Assays (Applied 
Biosystems) containing specific primers and probes (accession numbers: CCL3, 
Mm00441258_ml; CCL4, Mm00443111_m1; CCL5, Mm01302428_ml; GAPDH, 
Mm99999915_g1) and TaqMan® Fast Universal PCR Master Mix were used with 10 ng cDNA 
to quantify the expression levels of CCL3, CCL4, and CCL5. Reactions were performed for 20 
s at 95°C followed by 40 cycles of 1 s at 95°C and 20 s at 60°C. GAPDH was amplified as an 
internal control and their CT values were subtracted from CT values of the target genes (ΔCT). 
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ΔCT values of tumors after RFA with or without ECI301 were compared to ΔCT values of tumors 
of untreated mice. 
 
Enzyme-linked immunospot assay (ELISPOT)  
To prepare tumor lysates, BNL or CT26 cells were suspended in PBS and subjected to four 
cycles of rapid freezing in liquid nitrogen and thawing at 55°C. The lysate was spun at 15,000 
rpm to remove particulate cellular debris. After harvesting murine spleens on day 21 after RFA, 
mononuclear cells were isolated by centrifugation through a Histopaque-1083 density gradient 
(Sigma Chemical Co.). ELISPOT was performed using an IFN-γ-ELISPOT kit (Mabtech, 
Nacka, Sweden). Ninety-six-well plates coated with anti-mouse interferon-γ antibody were 
blocked for 2 h with RPMI 1640 medium (Sigma Chemical Co.) containing 10% FBS. Two 
hundred and fifty thousand splenic mononuclear cells were added in triplicate cultures of RPMI 
1640 containing 10% FBS together with BNL or CT26 lysates at a tumor cell-to-mononuclear 
cell ratio of 2:1. After 48 h of culture, the plates were washed eight times with sterile PBS and 
further incubated 2 h with biotinylated anti-mouse IFN-γ antibody. After another eight washes, 
alkaline phosphatase-conjugated streptavidin was added to these plates and incubated for 1 hr. 
Finally the spots were developed with NBT/BCIP solution. The numbers of specific spots were 
determined by subtracting the number of spots in wells without lysates from the number of spots 
in wells with tumor lysates. Wells were considered as positive if they had more than 10 spots 
per well and were at least twofold greater than control.  
 
Flow cytometric analysis 
After harvesting blood samples from mice, mononuclear cells were isolated by centrifugation 
through a Histopaque-1083 density gradient (Sigma Chemical Co.). The resultant single-cell 
preparations were stained with various combinations of APC-labeled anti-CD8, APC-labeled 
anti-CD11c, FITC-labeled anti-CD4 (BD Biosciences), PE-labeled anti-CCR1 (Santa Cruz 
Biotechnology), and FITC-labeled anti-F4/80 monoclonal antibodies (Serotec). APC-rat IgG, 
APC-hamster IgG, and FITC-rat IgG were used as isotype controls (BD Biosciences). For each 
determination, at least 20,000 stained cells were analyzed on a FACSCalibur system (BD 
Biosciences). The data were expressed as a proportion of positive cells (compared to cells 
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stained with an irrelevant control antibody).  
 
Depletion of macrophages/monocytes 
Clodronate liposome was prepared and systemic depletion of monocytes/macrophages was 
performed as previously described (20, 21). WT mice were intraperitoneally injected with 200μl 
of clodronate liposome 5 times; days -2, 0, 3, 6, and 10 after RFA treatment. Depletion of 




Mean and SD or SE were calculated for the obtained data. Data were analyzed statistically using 
one-way ANOVA followed by the Fisher’s PLSD test, except for the data of tumor growth 





ECI301 augments RFA-induced antitumor effects.  
In order to investigate the effects of RFA against RFA-treated and non-RFA-treated tumors, each 
bilateral flank of BALB/c mice was injected with 5×105 of BNL cells. Fourteen days later, when 
tumor size reached a diameter of 6–8 mm, tumors of one flank were treated by RFA treatment. 
On the day after RFA, ulceration occurred in RFA-treated tumors, and these tumors started to 
shrink (data not shown). On day 14 after RFA, RFA-treated tumors were covered with scars 
without any macroscopic tumors (Fig. 1A). Moreover, RFA treatment also retarded the growth 
of contralateral non-RFA-treated tumors compared with the tumors in untreated mice (Fig. 1B 
and C). Twenty µg/mouse of ECI301 administered on day 0, 2, 4 after RFA augmented 
RFA-induced growth retardation of contralateral non-RFA-treated tumors (Fig. 1B and C). 
Furthermore, non-RFA-treated tumors completely disappeared in 2 of 15 mice treated with RFA 
and ECI301 but not in the other treatment groups (Fig. 1B and C). Therapeutic effects were 
observed, even when 2 µg/mouse of ECI301 was injected consecutively for 5 days from day 0 
to 4 after RFA. On the contrary, administration of ECI301 without RFA did not result in a 
significant decrease in tumor size (Fig. 1C). These observations suggest that ECI301 can 
augment RFA-induced antitumor effects but fails to induce antitumor effects by itself. 
 
Deficiency of CCR1 abrogates increased antitumor effect of ECI301 after RFA. 
ECI301 utilizes two distinct chemokine receptors, CCR1 and CCR5. In order to elucidate the 
roles of these chemokine receptors, either tumor-bearing CCR1-/- or CCR5-/- mice was similarly 
treated with RFA plus ECI301. RFA retarded the growth of non-RFA-treated tumors in CCR1-/- 
mice similar to that in WT mice, but ECI301 failed to further accentuate RFA-induced growth 
retardation of non-RFA-treated tumors (Fig. 2A). In contrast, ECI301 augmented RFA-mediated 
inhibition of non-RFA-treated tumors in CCR5-/- mice, resulting in complete tumor eradication 
in 1 of 6 mice (Fig. 2B). These observations indicate that CCR1- but not CCR5-expressing cells 
play an important role in ECI301-induced augmentation of tumor regression after RFA. 
 
ECI301 increases CCR1-expressing cells in peripheral blood and RFA-treated tumors 
Iida 11 
after RFA. 
The reported capacity of CCL3 to mobilize leukocytes into peripheral blood (15, 16), prompted 
the investigation of the effects of ECI301 on peripheral blood. RFA alone had few effects on the 
numbers of CCR1-expressing cells, but subsequent ECI301 administration increased the 
numbers of CCR1-expressing cells in peripheral blood, particularly CD11c+ but not CD4+ or 
CD8+ cells (Fig. 3). Because immune cells need to accumulate into RFA-treated tumors at an 
early stage in order to initiate adaptive immune responses, CCR1 expression by 
tumor-infiltrating cells into RFA-treated tumors was examined 8 h after treatment. RFA-induced 
CD4+, CD8+, CD11c+, and F4/80+ cell infiltrations into RFA-treated tumors was greater than 
those into tumors of untreated mice. Moreover, ECI301 further increased the numbers of 
tumor-infiltrating CD4+, CD8+ and CD11c+ cells into RFA-treated tumors compared with the 
numbers of these cells infiltrating tumors treated with RFA alone (Fig. 4A and B). In 
RFA-treated tumors, most CD11c+ and F4/80+ cells expressed CCR1, whereas a few CD4+ and 
CD8+ cells expressed CCR1 (Fig. 4C). Furthermore, ECI301-induced CD4+, CD8+, and CD11c+ 
cell infiltrations into ablated tumors was lesser in CCR1-/- mice than in WT mice, whereas 
F4/80+ cells infiltrated RFA-treated tumors in CCR1-/- mice and WT mice to a similar extent 
(Fig. 4D). These observations suggest that ECI301 augments RFA-induced CD4+, CD8+ and 
CD11c+ cell infiltrations into RFA-treated tumors in a CCR1-dependent manner.  
 
ECI301 increases intratumoral expression of CCL3 after RFA. 
We demonstrated that CCR1+ cells were mobilized into blood by intravenously administered 
ECI301. However, concentration of ECI301 in blood can go down rapidly as time passes (the 
peak is 5 minutes, and the half-life is less than 2 hours; unpublished data from Effector Cell 
Institute), allowing ECI301-mobilized CCR1+ cells possibly to migrate into tissues where 
chemokines are highly produced. In order to prove this point, chemokine expression in 
RFA-treated tumors was examined. RFA plus ECI301 treatment increased CCL3 mRNA 
expression level 6 hours after RFA. Moreover, 24 hours after the treatment, CCL3 and CCL4 
mRNA expression level became almost 10-fold higher in tumors treated with RFA alone than in 
tumors of untreated mice, and ECI301 further increased the mRNA expression level of these 
chemokines in RFA-treated tumors (Fig. 5A). CCL3 and CCL4 were detected in 
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tumor-infiltrating F4/80+ cells (Fig. 5B). These observations indicated that RFA treatment 
caused local production of CCL3 and CCL4 in RFA-treated tumors and ECI301 further 
increases the expression of these chemokines. As the concentration of ECI301 in blood 
decreases, chemokines produced locally in RFA-treated tumor can attract CCR1-expressing 
CD11c+ cells, thereby indirectly inducing CCR1-negative CD4+ and CD8+ cell infiltrations.  
 
ECI301 augments RFA-induced tumor-specific immune responses accompanied with T-cell 
infiltrations into non-RFA-treated tumors. 
Non-RFA-treated tumors were analyzed histologically to clarify the mechanisms 
underlying the CCR1-dependent inhibitory effect of RFA plus ECI301 treatment against these 
tumors. Although a few CD4+ or CD8+ cells were observed in the tumors of untreated mice, 
RFA treatment increased the numbers of CD4+ and CD8+ cells in the non-RFA-treated tumors 3 
days after RFA. ECI301 further augmented RFA-induced CD4+ and CD8+ cell infiltration into 
non-RFA-treated tumors (Fig. 6A and B). However, only a marginal number of CD11c+ or 
F4/80+ cells infiltrated into non-RFA-treated tumors of mice treated with RFA alone or RFA plus 
ECI301-treated mice (data not shown). Based on these findings, we hypothesized that 
ECI301-augmented tumor regression after RFA may be associated with T-cell-mediated 
antitumor immune responses. To clarify this point, BALB/c-background nu/nu mice were 
treated by RFA with or without ECI301. Deficiency of T cells abrogated tumor-inhibitory effect 
of ECI301 as well as RFA-induced antitumor effect (Fig. 6C). Thus, both ECI301- and 
RFA-induced tumor regression require T cell-mediated antitumor immune response. 
However, CD4+ or CD8+ T cells rarely expressed CCR1 in blood and RFA-treated 
tumors. CCR1+ cells in the RFA-treated tumors were CD11c+ cells and F4/80+ cells, and only 
the former accumulates into the RFA-treated tumor in a CCR1-dependent manner. These 
findings suggest that CCR1-positive CD11c+ cells may activate antitumor T-cell responses and 
indirectly induce tumor retardation. Accordingly, we next examined the effect of depletion of 
monocytes/macrophages on ECI301-augmented tumor regression. Intraperitoneal injection of 
clodronate liposome depleted CD11c-negative monocytes in blood, although it didn’t change 
the number of CD11c+ cells (data not shown). Depletion of these CD11c-negative monocytes 
didn’t cause any effects on ECI301-enhanced tumor regression, indicating that 
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ECI301-augmented antitumor T-cell immunity was independent of CD11c-negative monocytes  
(Fig. 6C). 
Finally, in order to prove the presence of systemic adaptive immune responses, IFN-γ 
ELISPOT assay was performed using mononuclear cells from the spleen. A greater number of 
spots against BNL cell lysates but not against CT26 cell lysates were generated by RFA plus 
ECI301-treated mice than that by mice treated with RFA alone or untreated mice. Moreover, 
ablation of CCR1 but not CCR5 gene reduced the number of spots against BNL cell lysates even 
when the mice were treated with RFA plus ECI301 (Fig. 6D). These observations suggest that 
ECI301 can further augment RFA-induced tumor-specific adaptive immune responses and 
subsequent tumor retardation in a CCR1-dependent manner.  
Iida 14 
DISCUSSION 
HCC occurs predominantly in individuals with chronic liver disease related to either 
hepatitis B or C virus infections (22-24). In addition to surgical resection, RFA treatment has 
been developed to eradicate solitary HCC lesions (25). RFA of HCC induces specific T-cell 
responses against liver tumors in human and rabbit (8, 11). Moreover, activated dendritic cells 
were detected in peripheral blood of HCC patients after RFA (9). These previous reports 
indicate that RFA treatment can induce antitumor immune responses against HCC (8-11). 
Likewise, we observed that RFA treatment generated tumor-specific IFN-γ-producing cells and 
inhibited the growth of non-RFA-treated tumors accompanied with massive T-cell infiltration 
into these tumors. However, even after successful ablation of HCC lesion by RFA, tumor 
recurrence often occurs probably because HCC develops in a multicentric manner in the 
cirrhotic liver (12). These observations indicate that RFA-induced augmentation in immune 
response may not be sufficient to prevent tumor recurrence. Thus, a novel therapeutic modality 
is required to further augment RFA-induced tumor-specific immune responses. Here, we 
demonstrated that combined administration of ECI301 and RFA can augment tumor-specific 
immune responses against HCC. 
Several chemokines are used for immunotherapy against cancers because they can 
attract immune cells such as dendritic and cytotoxic T cells to augment tumor specific immune 
responses (26). However, some chemokines can simultaneously attract myeloid-derived 
suppressor and regulatory T cells to promote neovascularization and induce immunosuppressive 
microenvironments (26-28). The double-edged activities of chemokines frequently preclude 
their use for tumor immunotherapy. Moreover, most chemokines exhibit a bell-shaped 
dose-response curve with a narrow effective dose window. Thus, determination of an optimal 
dose of chemokines is important to elicit efficient antitumor responses (29). Several lines of 
evidence demonstrate that intratumoral use of CCL3 reduces tumorigenicity (6, 30). 
Furthermore, there are no reports demonstrating that use of CCL3 can promote tumor 
progression. We observed that systemic administration of ECI301 without RFA treatment 
induced neither reduction nor progression of tumors. On the contrary, systemic injection of 
ECI301 after RFA can inhibit growth of non-RFA-treated tumors in the contra-lateral side. 
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ECI301-enhanced tumor regression after RFA was both CCR1-dependent and T cell-dependent, 
but T cells rarely expressed CCR1 in blood and RFA-treated tumors. Because depletion of 
monocytes/macrophages didn’t affect the retardation of ECI301-treated tumors, 
CCR1-expressing CD11c+ DC might activate antitumor T-cell responses and indirectly induce 
tumor retardation via some mechanisms such as antigen-presentation and cytokine-production. 
ECI301 mobilized a large number of CCR1+ cells into blood, and these mobilized cells may be 
attracted into highly CCL3-producing RFA-treated tumors and cause increased number of 
tumor-infiltrating CCR1+CD11c+ DC. Thus, CCR1+ precursors in blood and CCR1+CD11c+ 
tumor-infiltrating DC might play important roles in ECI301-augmented antitumor effects 
(31-33).  
ECI301 could not increase the number of F4/80+ cells in the RFA-treated tumor sites. 
Accumulation of F4/80+ cells in the tumor treated with ECI301 plus RFA was also independent 
of CCR1. F4/80+ cells, which might include a large number of macrophages/monocytes, are 
usually attracted into the tumor by CCL2, CCL4, and CCL5 that are produced in the tumor sites. 
CCR2, the receptor for CCL2, and CCR5, the receptor for CCL4 and CCL5, might be 
responsible for migration of monocytes/macrophages (27, 34-36). However, it is still unclear 
whether monocytes/macrophages utilize CCR2 or CCR5 after massive tumor cell death caused 
by the treatments such as RFA, because tumor cell death induces different profile of chemokine 
production in the tumors (4). Although ECI301 didn’t directly induce migration of F4/80+ cells, 
the mechanism underlying the infiltration of F4/80+ macrophages remains to be elucidated.  
Breaking tolerance for tumor cells is necessary for induction of antitumor immunity. 
Several independent groups have suggested multiple mechanisms underlying immunogenic 
tumor cell death induced by anti-cancer chemotherapy or radiation therapy (37-40). 
Anthracyclin causes apoptosis along with translocation of calreticulin to the apoptotic tumor 
cell surface. Calreticulin exposure augments phagocytosis of apoptotic cancer cells by dendritic 
cells with an eventual increase in immune response (37, 38). Chemotherapy or irradiation kills 
tumor cells to release high mobility group box 1 (HMGB1). Released HMGB1 activates 
dendritic cells after binding to toll-like receptor 4 expressed by these cells (39). Apoptosis 
induced by local radiation therapy augments MHC class I expression by tumor cells, thereby 
facilitating their recognition by cytotoxic T cells (40). RFA induces the expression of heat shock 
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protein 70 and 90 on ablated tumor cells, and these proteins can activate TLR-expressing 
antigen presenting cells (41, 42). In addition, we demonstrated that RFA treatment alone caused 
local production of CCL3 in RFA-treated tumors accompanied with accumulation of T-cells and 
CD11c+ DC. These mechanisms may also account for the observed RFA-induced generation of 
tumor-specific immune responses. 
We revealed that combined treatment of ECI301 and RFA augmented 
antitumor-specific immune responses, thereby inhibiting the growth of non-RFA-treated tumors 
in a CCR1-dependent manner. Thus, combined treatment of ECI301 and RFA can prevent 
human HCC from recurring after RFA treatment. Absence of any severe adverse effects in mice 
(data not shown) may further warrant the clinical trial of ECI301 combined with RFA as a 
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Figure 1. ECI301-induced augmentation of antitumor effects after RFA. 
WT mice were injected subcutaneously with 5 × 105 BNL cells into the left and right flanks. 
Fourteen days later, when tumors became palpable, tumors of one flank were treated using the 
RFA generator and needle. On day 0, 2, 4 after RFA, 20 μg of ECI301 in 100 μl PBS was 
injected intravenously into each mouse, while mice treated with RFA alone were injected with 
100 μl PBS. Tumor-bearing untreated mice were observed as controls. (A) Macroscopic 
appearances of the mice on day 14 after RFA are shown. Arrow heads indicate the scar after 
RFA. Representative results are from at least 10 mice in each group. (B) Non-RFA-treated 
tumor volumes (mean and SE) after RFA with or without ECI301 were measured twice a week. 
*p < 0.05; ***p < 0.001. (C) Volumes of non-RFA-treated tumors on day 14 after RFA. In 
addition to the groups described in Fig. 1B, tumor volumes (mean and SE) were determined in 
animals receiving 2 μg of ECI301 in 100 μl PBS intravenously from day 0 to 4 (5 consecutive 
days) after RFA and those receiving 20 μg of ECI301 alone without RFA. *p < 0.05; **p < 0.01; 
***p < 0.001 compared with untreated mice.  
 
Figure 2. Deficiency of CCR1 abrogated ECI301 augmented antitumor effects after RFA.  
CCR1-/- or CCR5-/- mice were inoculated with BNL cells and treated as described in the legend 
to figure 1. Non-RFA-treated tumor volumes (mean and SE) were measured twice a week on 
CCR1-/- (A) or CCR5-/- mice (B). *p < 0.05; **p < 0.01. 
 
Figure 3. ECI301 increased CCR1-expressing cells in peripheral blood. 
Peripheral blood sample was harvested 8 h after RFA. Mononuclear cells were separated and 
stained with indicated antibodies as described in Materials and Methods. The percentages of 
CCR1+, CCR1+CD4+, CCR1+CD8+, CCR1+CD11c+, or CCR1+F4/80+ cells were determined and 
are indicated. Mean and SD were calculated and are shown here (n = 3). *p < 0.05. 
 
Figure 4. ECI301 increased infiltration of CCR1-expressing leukocytes into RFA-treated 
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tumors after RFA.  
RFA-treated tumors were removed from WT or CCR1-/- mice 8 h after RFA. (A), (B), and (D) 
Immunohistochemical analysis was performed using anti-CD4, anti-CD8a, anti-CD11c, or 
anti-F4/80 antibodies. Representative results from 3 individual WT mice in each group are 
shown in A. Original magnification, ×400. Bar, 50 m. The numbers of CD4+, or CD8+, CD11c+, 
or F4/80+ cells were counted. Cell density was determined in 10 randomly chosen tumor areas at 
400-fold magnification. Mean and SD were calculated and are shown in B and D (n = 5). **p < 
0.01. (C) RFA-treated tumor tissues were processed using double-color immunofluorescence 
analysis as described in Materials and Methods. Right panels represent digitally merged images. 
Representative results from 3 individual animals are shown here. Original magnification, 400. 
Bars, 50 m. 
 
Figure 5. Increased CCL3 expression in RFA-treated tumors.  
(A) Real-time RT-PCR was performed on total RNA extracted from RFA-treated tumor of WT 
mice. The tumors were harvested 6 hours after RFA (left) or 24 hours after RFA (right). 
Chemokine mRNA level was normalized to GAPDH mRNA levels. Mean and SD were 
calculated and are shown here (n = 3). *p < 0.05 compared with untreated mice. (B) 
RFA-treated tumors were removed from WT mice on day 1 after RFA plus ECI301 treatment 
and immunostained with the indicated combinations of antibodies as described in Materials and 
Methods. The digitally merged images are shown in the right panels. Representative results 
from 3 individual animals are shown here. Original magnification, ×400. Bars, 50 μm.  
 
Figure 6. ECI301 augmented tumor-specific immune responses after RFA. 
(A) Non-RFA-treated tumors were removed from WT mice on day 3 after RFA and 
immunohistochemical analysis was performed using anti-CD4 or anti-CD8a antibodies. 
Representative results from 3 individual animals in each group are shown here. Original 
magnification, ×400. Bar, 50 μm. (B) The number of CD4+ or CD8+ cells was counted. Cell 
density was determined in 10 randomly chosen tumor areas at 400-fold magnification. Mean 
and SD were calculated and are shown here (n = 5). **p < 0.01. (C) BALB/c-nu/nu mice (left) 
and BALB/c-WT mice (right) were inoculated with BNL cells and treated as described in the 
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legend to figure 1. In RFA+ECI301+clodronate liposome (CL) group, the mice were injected 
with 200μl of CL to deplete monocytes/macrophages as described in Materials and Methods. 
Non-RFA-treated tumor volumes (mean and SE) were measured twice a week. (D) Spleens from 
WT, CCR1-/-, or CCR5-/- mice were harvested on day 21 after RFA, and mononuclear cells were 
separated from the spleens for ELISPOT assay as described in Materials and Methods. The 
numbers of specific spots (mean and SD) were determined by subtracting the number of spots in 
wells without lysates from the number of spots in wells with tumor lysates (n = 3). *p < 0.05; 
**p < 0.01 compared with untreated WT mice. 
 






